Experiments were performed strictly following the Guide for Care and Use of Laboratory Animals approved by the National Institutes of Health (NIH)
VPS35 regulates mitochondrial fusion protein 2 (Mfn2) by controlling the transport of mitochondrial ubiquitin ligase 1 (MUL1) to the mitochondrial membrane, promoting mitochondrial fusion, which in turn increases ATP production and reduces mitophagy [105]
Figure 1 illustrates this intricate interaction, known as the pancreas-intestine-lung pathway, which encompasses intestinal barrier disruption, bacterial translocation, and the widespread activation of inflammatory cascades
[1] [2] [3] [20] Although clinical trials evaluating the efficacy and safety of NAD+-replacement therapy or augmentation in the context of human disease and aging have recently been completed, many more are still in progress
Studies examining how this compound influences these enzymatic activities in controlled laboratory conditions have contributed to the understanding of the GH C-terminal fragments role in adipose tissue biology